Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aldo-keto reductase from Streptomyces fradiae (AKR12A)
- Target
- AKR12A
- Molecular classification
- Enzyme, Oxidoreductase, Aldo-keto reductase superfamily, AKR12 family (AKR12A subfamily, specific for this gene/protein)
01
Overview
Aldo-keto reductase from Streptomyces fradiae (AKR12A) is an NADPH-dependent oxidoreductase from the AKR12 family, part of the larger aldo-keto reductase (AKR) superfamily. It catalyzes the stereospecific reduction of carbonyl groups, specifically converting tylosin (a macrolide antibiotic) into relomycin as part of antibiotic biosynthetic pathways in S. fradiae. AKR enzymes share a common (β/α)₈ (TIM barrel) structural fold, broad substrate specificity, and play vital roles in microbial metabolism, including secondary metabolite biosynthesis and detoxification. The enzyme is of particular industrial interest for modulating antibiotic composition during fermentation, but does not have a direct therapeutic or diagnostic application in humans
- Other names
- AKR12AStreptomyces fradiae aldo-keto reductaseStreptomyces sugar aldehyde reductase (in the context of AKR12 family)
02
Mechanism of action
NADPH-dependent reduction of the macrolide tylosin at a specific carbonyl position to yield relomycin (mechanism is a classical AKR hydride transfer with cooperation between catalytic residues and NADPH cofactor)
03
Biological functions
Carbonyl group reduction (aldehydes and ketones to alcohols)Secondary metabolite biosynthesis (antibiotic biosynthesis adaptation in S. fradiae)Detoxification and biotransformation of endogenous or exogenous carbonyl compounds
04
Disease associations
Infection (S. fradiae is a producer of tylosin, an antibiotic active against bacterial infection; alterations in the enzyme could influence tylosin production and potentially resistance mechanisms in host or environment)Other (industrial/biotechnological manipulation for antibiotic yield optimization)No direct human disease implication reported
05
Safety considerations
None noted for the target itself; as an industrial/biotechnological reagent, general concerns would be limited to bioprocess safety. There are no described concerns for clinical use as a direct therapeutic target.
06
Interacting drugs
Tylosin (natural substrate, macrolide antibiotic)
2 more in the full profile.
07
Biomarkers
None established for patient selection or efficacy monitoring; the enzyme is a bacterial biosynthetic enzyme, not directly a clinical biomarker
Beyond the preview
Go deeper on Aldo-keto reductase from Streptomyces fradiae (AKR12A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldo-keto reductase from Streptomyces fradiae (AKR12A).